A Randomised, Single-blind, Placebo-controlled, Dose-escalation Study to Assess the Safety and Tolerability of Single and Repeat, Inhaled Doses of PC786 in Healthy Subjects Combined With a Randomised, Single-blind, Placebo-controlled, Parallel Group to Assess the Safety and Tolerability of a Single Dose of Inhaled PC786 in Subjects With Mild Asthma
Phase of Trial: Phase I
Latest Information Update: 27 Dec 2017
At a glance
- Drugs PC-786 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors Pulmocide
- 20 Dec 2017 Status changed from active, no longer recruiting to completed.
- 05 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Aug 2017 New trial record